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Summary: The expert group "Drug Interference in Clinical Chemistry" of the Bureau of Reference, Directorate
General for Research, Science and Education of the Commission of the European Communities, consisting of one
participant of each member of the European Communities, presents this first report on the final results of its
activities.
Within the framework of a first stage basic program, the paper describes interferences of therapeutic and elevated
doses of ascorbic acid on commonly used clinical chemical methods. This is the result of a bipartite study that was
jointly planned, carried out and evaluated. Local and personal influences have been eliminated, as have variations due
to methodology, measurement equipment and reagents, in order to be able to present distinct causal effects of
ascorbic acid.
No definite influence of ascorbic acid on analytical values for urea, cholesterol, calcium, protein, bilirubin, aspartate
aminotransferase and alkaline phosphatase could be detected.
At therapeutic concentrations, ascorbic acid distinctly interferes with the analysis of glucose, uric acid, creatinine
and inorganic phosphate. The extent and direction of interferences vary, depending on the type of reaction, kit and
apparatus. In some cases the influence of ascorbic acid results in severe disturbance of the analytical methods leading
to useless values.
Arzneimittelstörungen in der Klinischen Chemie: Untersuchungen mit Ascorbinsäure
Zusammenfassung: Die Expertengrüppe "Drug Interference in Clinical Chemistry" des "Büro für Standardisierung"
im Generalsekretariat für Forschung, Wissenschaft und Erziehung der Europäischen Gemeinschaft, legt erste Ab-
schlußergebnisse ihrer Tätigkeit vor. Im Rahmen eines vorab erarbeiteten Grundsatzprogramme werden in einer
gemeinsam geplanten, durchgeführten und ausgewerteten zweiteiligen Studie Störeinflüsse von therapeutischen und
hohen Dosen von Ascorbinsäure auf gebräuchliche klinisch-chemische Untersuchungsmethoden beschrieben.
Nicht oder statistisch nicht sicherbar beeinflußt werden Bestimmungsmethoden für Harnstoff, Cholesterin, Calcium,
Protein, Bilirubin, Aspartataminotransferase und alkalische Phosphatase.
Eindeutige Beeinflussungen bereits bei therapeutischen Ascorbinsäurekonibmationen liegen vor bei Glucose, Harn-
säure, Kreatinin und anorganischem Phosphat. Ausmaß und Richtung der Störung variieren in Abhängigkeit von
Reaktionstyp, Reagenzierikombination und Gerät. In einigen Fällen fuhrt der Einfluß der Ascorbinsäure zu schweren
Störungen der analytischen Methode bis zur Unbrauchbarkeit der Werte.
Introduction in laboratory tests. Drugs are predominant among these
t · _ , factors, owing to their interference with analytical
The development of a wide range of biological tests, ^^
 a$ we]1 as their pharmacological effects; there
mechanisation, and data processing have contributed to .§ ^  extensive iiterature on this problem (1-19).
the discovery of many factors that cause variations
—- —~~~^ , ^ ,„ * , * ^- Indeed, the interpretation of a laboratory result usingl)Dr. Lauer died in August 1976. We are deeply grateful for his , . ' . V.
 u + . . « · «, ·
everlasting assistance colorunetric, spectrophotometnc, fluorimetnc or en-
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zymatic methods may be difficult and even erroneous
due to the following factors:
Analytical factors
Quality control is designed to detect most of these errors.
The evolution towards more accurate and more specific
techniques will make it possible to avoid, or at least
control such errors.
Physiological or environmental factors
Variations due to age, sex, exercise, meal intake etc. are
now well known, but the interference of environmental
factors, such as climatic conditions, dietary habits,
pesticides, and, of course, drugs, is also considerable and
often more important.
With respect to environmental factors, it was considered
necessary to initiate a systematic study of analytical
interferences.
For this purpose a working sub-group "Drug Interference
in Clinical Chemistry" (20) was founded by the Bureau
of Reference, (Dr. Lauer) Directorate General for
Research, Science and Education of the Commission of
the European Communities. This group of experts
consists of delegates of the national clinical chemical
societies.
Within the framework of this group of experts in the
European Communities the following goals shall be
pursued:
1. Establish and keep an up-to-date list of drugs which
are likely to effect reference and routine methods.
2. Prepare a protocol for the study of analytical inter-
ferences.
3. Seek out the methods least sensitive to analytical
interference from drugs and their metabolites.
4. Prepare a control serum containing drugs and metabo-
lites.
5. Establish the percentage interference due to drugs, to
be used by clinical chemists and clinicians for correct
interpretation of laboratory results.
Details concerning general rules, guide lines and first
results up to 1975, have already been presented by Siest,
Lauer et. al. (20) at Pont Mousson and byAppel,
Lauer et al. at Munich, 1976 (21).
In this paper results relevant to points 2—5 above are
presented. Ascorbic acid was selected in preference to
acetyisalicylic acid as the first substance to be investi-
gated by the above mentioned expert group. It was
necessary to test a simple drug molecule that was easy to
find commercially in a pure state, and that was known
to interfere with certain tests used in clinical chemistry.
Ascorbic acid fulfills these criteria and was chosen as a
model for the general protocol.
Materials and Methods
For this study, commercially available ascorbic acid (no special
lot) and commercial, lyoph ized human serum were chosen. An
ascorbic acid overdose was simulated by mixing the control
serum (redissolved in distilled water) and an "overloaded serum"
(redissolved in an aqueous solution of ascorbic acid) (See
Annexe "General protocol").
Data on the parameters studied, analytical methods, apparatus
and technical equipment are given in table 1.
First study
The concentrations tested during the first study ranged from
0-2 g/1 of ascorbic acid. Methods listed in table 1 were studied.
Measurements were performed in duplicate on each overloaded
solution.
The sera were prepared daily, and the analyses were carried out
on 5 consecutive days by routine methods within routine work
at 8 laboratories of different members of the expert group in
different countries of the European Communities. The results
are presented in μηιοΐ/ΐ or in mmol/1 depending upon the para-
meter, accompanied by specifications of the equipment used,
techniques and variation coefficient in the zone of values meas-
ured.
Since the parameters showed a more or less clear interference,
additional statistical studies were carried out (table).
- Test of significance between control (dose 0) and the first
ascorbic acid overdose (0.71 mmol/1) for each laboratory, for
all laboratories together, regrouping laboratories according to
the techniques used.
- A 2-factor variance analysis was performed for each laboratory
result. This made it possible to determine the significance of
the difference between the control serum and the first serum
(first concentration). Other analyses of variance were per-
formed on the same parameters: one by regrouping all the
laboratories, the other by regrouping laboratories using the
same techniques (tab. 2).
Second study
This study was then extended in 4 laboratories, in order to
identify the parameters that cause a distinct interference.
Additional assays were performed at the following concen-
trations that are close to the therapeutic values: 0.14 mmol/1,
0.34 mmol/1, 0.71 mmol/l, 1.42 mmol/1. On the basis of this
study with ascorbic acid, we have established a general protocol
for the study of drug interference (cf. annexe).
The distribution of protocols and questionaires, samples of
ascorbic acid and serum to each participant of the study, the
collection and mathematical-statistical evaluation of experi-
mental data and the preparation of results were performed under
the supervision of the Chairman of the g'roup, Dr. Siest (14)·
Discussion of results took place at the group's meetings at
Geneva and Pont a Mousson.
Results
The evaluated "General protocol of analytical inter-
ference by ascorbic acid" is shown in the annexe.
First study
For certain parameters, no comment is called for, either
because there is no interference, i.e.
Urea, Cholesterol, Calcium and Protein',
or because the dispersion is too great and the variations
are not systematic, i.e.
Bilirubin,AspartateAminotransferase',
or because of the technical problems encountered, i.e.
Alkaline Phosphatase.
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Tab. 1. Methods: Objectives, analytical methods, apparatus, and technical equipment.
Objectives Method Instrument
Aspartate aminotransferase
Phosphatase, alkaline
Bilirubin
Calcium
Cholesterol
Creatinine
Glucose
Phosphate, inorganic
Protein, total
Urea
Uric acid
UV-test, kinetic, opt.
UV-test, kinet. non opt.
UV-test, end point
Colorimetric test
Kinetic-test, p-nitrophenyl phosphate, buffer: diethanolamine
Kinetic-test, p-nitrophenyl phosphate, buffer: glycine
End-point-test, p-nitrophenyl phosphate, buffer: 2-amino-
2-methyl-l-propanol
End-point-test, p-nitrophenyl phosphate
End-point-test, phenyl disodium phosphate
Sulfanilic acid-caffein
Dichloraniline-nitrite
o-Cresolp hthalein-complexon
Flame photometry
Thymolphthalein-complexon
Calcein
Acetic aiihydrideracetic acid Lieb er mann-Bur chard, Huang,
Watson
Esterase/oxidase-catalase
Esterase-hydrogen peroxidase
Alkaline picrate (Jaffe) without deproteinisation
Alkaline picrate (Jaffe) with dialysis
Picric acid, kinetic test
Glucose oxidase-Perid
Glucose oxidase-peroxidase
Glucose oxidase-TV/mfe/' method
Neocuproin
Molybdate-hydroquinone-ascorbate
Molybdate-p-methylaminophenolsulfate
Molybdate-vanadate
Molybdic acid-stannous chloride-hydrazine
Biuret-reaction
Diacetylmonoxime
Ureaserdiacetylmonoxime
Urease-Ffl wzett-Sco tt
Urease-glutamate dehydrogenase
Urease-nitroprussiderphenol
Phosphotungsticacid-hydrpxylamine
Uncase
Uricase-Ca^neocuproin
Eppendorf 5020
LKB 8600
ABA 100
Greiner GSA II
SMA 12/60
Autochemist
ACA DuPont
Eppendorf 5020
LKB 8600
SMA 12/60
ACA DuPont
Greiner GSA II
Beckman DSA
SMA 12/60
Autochemist
SMAC
SMA 12/60
Eppendorf 1101
Beckman DSA
Autochemist
Bilirubinometer
Greiner GSA II
SMA 12/60
ACA DuPont
SMAC
Zeiss PF 5
Autochemist
Greiner GSA II
Oxford Titrator
SMA 12/60
Eppendorf 1101
Autochemist
LKB 7400
ABA 100
Greiner GSA II
Autochemist
SMA 12/60
LKB 8600
Eppendorf 5020
SMA 12/60
Vitatron UC 200 S
LKB 7400
Gilford
SMA 12/60
Autochemist
Eppendorf 1101
LKB 7400
SMA 12/60
SMAC
SMA 12/60
Greiner GSA II
ACA DuPont
LKB 2071/7400
Beckman DSA
C 4 Perkin Elmer
Vitatron UC 200
SMA 12/60
SMA 12/60
Greiner GSA II
Eppendorf 5 020
LKB 2071/7400
ACA DuPont
Autochemist
SMA 12/60
Eppendorf 1101
LKB 2071/8600
Autochemist
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Tab. 2. Variation coefficients (CV), level of significance between dose 0 and dose 1 (0.71) mmol/1)
GOD = glucose oxidase F = — = critical values in 2-factor variance analysis testing the null hypothesis at 0.05 (= 5%)
sy
significance levels.
Glucose
Lab. CV
No. [%]
1
3
6
7
8
2
4
5
All lab.
Lab. 1,
1 10
4 19
1 1
1 15.4
4 7.8
t 4
t 2.1
t 2
3,7,8
(GOD Perid)
Lab. 2, 4-6
(neocuproin)
Uric acid
level lab.
of No.
significance
0.001
0.001
n.s.
0.001
0.01
0.001
0.01
0.001
F
4.44
0.05
15.64
0.001
0.41
n.s.
1
3
7
2
4
5
6
8
all lab.
lab. 2-6
CV
[%]
4 1.7
4 1.1
1 1.6
ί 6.2
t 5.3
t 5.4
ί 6.8
ί 55.3
Inorganic phosphorus Creatinine
level lab. CV level lab. CV
of No. [%] of No. (:%]
significance significance
ri.s
n.s.
n.s.
0.001
0.001
0.001
0.001
0.001
F
11.4
0.001
5.14
0.01
1 41.5
2 iO.9
5 U
7 42.4
3 0
6 0
8 14.8
all lab.
lab. 2, 3, 5, 6
n.s.
n.s.
n.s.
n.s.
0.05
F
0.013
n.s.
0.065
n.s.
1
2
3
4
5
6
7
8
all lab.
lab. 2-6
t 4.9
t 0.1
t 9
t 2.2
12.4
t 2.3
t 3.1
t 6.7
level
of
significance
0.01
n.s.
0.01
0.05
n.s.
n.s.
n.s.
0.01
F
1.80
n.s.
0.97
n.s.
For other parameters, a more or less clear interference
is noted.
Glucose
Glucose oxidase methods yield results that are low
(22—25), neocuproin methods yield results that are high
with both methods (24, 26, 27); the variations are
statistically significant.
Uric acid
Methods using uricase are not affected by ascorbic acid
(28, 29) except when the second stage is based on copper
reduction. Phosphotungstate techniques are affected
significantly even at the lowest concentration of ascorbic
acid (5, 23, 25, 30-32).
Creatinine
Three laboratories use methods without deproteinization.
The interference is greater if measurement is preceded
by dialysis. This might be due to a change in physical
properties of the serum upon the addition of ascorbic
acid (33-35).
Inorganic Phosphate
The dispersion of results is great, the observed variations
do not appear to be significant.
Second study
The results of this second study are demonstrated by
four graphs.
Glucose (fig. 1)
Neocuproine methods show increasing, glucose oxidase-
Perid methods decreasing values with increasing concen-
trations of ascorbic acid; the effect is already apparent at
therapeutical levels of ascorbic acid.
Methods using glucose oxidase without indicator reaction,
hexokinaselglucQse-6'phosphate dehydrogenase or
glucose dehydrogenase respectively > are not influenced
by ascorbic acid.
Uric acid (fig. 2)
Phosphotungstate methods show increasing values with
increasing concentrations of ascorbic acid.
Uricase methods do riot behave in a uniform manner
depending on the nature of the secondary reaction:
Uricase-hydrazone methods yield greatly decreased
values, uricase neocuproin methods greatly increased
values, being useless with higher concentrations of
ascorbic acid.
The uncase/catalasejformaldehyde reaction (Kageyama)
is not affected (36).
Creatinine (fig. 3)
Jaffe's reaction, used in mechanized analysis systems
withput deproteinization, is influenced by ascorbic acid
in different ways. Methods with dialysis show a
primary decrease followed by an elevation up to normal
values.
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0.71 1.42 2.84 5.68
Ascorbic Qcid[mmol/l]
Fig. 1. Interference by ascorbic acid in glucose tests.
2, 4, 5, 6
1
3
7
Neocuproin SMA12/60
Glucose oxidase Vitatron UC 200 S +
Perid method Digilog DRP 200
Boehringer ref . 15754
Glucose oxidase-perid Technicon
Glucose oxidase- LKB 7400
peroxidase
Trinder method, Gilford
glucose oxidase
Kinetic methods tend to elevated values with increasing
amounts of ascorbic acid. All effects are more or less
pronounced depending on the type of reagent or kit.
Inorganic phosphate (fig. 4)
SnCly-hydrazine methods tend to lowered values with
higher concentrations of ascorbic acid, but the difference
is not significant.
Methods using hydroquinone-ascorbate, vanadate and
p-methylaminophenoi are not influenced by ascorbic
acid.
Discussion
The spread of results obtained by the 8 laboratories was
considerable. As in all surveys, there is primarily a
problem of accuracy. Each laboratory was not expected
to change its calibration. In a special trial, a serum
0.71 1.42 2.84 5.68
Ascorbic QCid(mmol / l l
1
Fig. 2. Interference by ascorbic acid in uric acid tests.
2,3,4,5,6 Phosphotungstic acid- SMA 12/60
hydroxylamine
Enzymatic color test Eppendorf 1101
Uricase, Boehringer
ref. 15865
UV test
Uricase-Boehringer
ref. 15986
Uricase-Cä^-neo-
cuproin
Uricase-hydrazone
LKB 2071-
LKB 8600
Auto-
chemist
having an "assigned" value was integrated into the series
and the results adjusted using this value. The addition
of the drug in vitro did not appear to increase the dis-
persion. Therefore, depending on the analytical systems,
principles of the methods, combinations of reaction
steps, reagents, kits, and instruments, it is not possible
to discuss in a simple way the factors concerned in the
interference by ascorbic acid. [
Methods that are not influenced by ascorbic acid are
listed in table 3- These results agree with the existing
literature. Table 4 shows those analytical methods for
glucose, uric acid, and creatinine that are regarded as
less recommendable. Concerning the risk of false inter-
pretation of results, the concentrations and pharma-
cokinetic data for ascorbic acid in vivo cannot be
neglected. The concentrations used in this study cover
the zone of therapeutic values (0-0.125 g/1 = 0-0.71
mmol/1) and likewise values which may be attained due
to therapeutic accidents (21). To achieve more in-
formation it is necessary to perform studies in vitro as
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108 Siest et al: Ascorbic acid interference in clinical chemistry
250
200
"o
150
100
50
/ 7 Tab. 3. Analytical methods not influenced by ascorbic acid.
7
_L
071 1.42 2.84 5.68
Ascorbic acid [mmot/1]
11.36
Fig. 3. Interference by ascorbic acid in creatinine tests.
2, 3, 4, 5, 6 Alkaline picrate + dia- SMA 12/60
lysis (Jaffe)
1 Kinetic test^picric Eppendorf 5020/11
acid Merckotest
ref. 3385 (without
deproteinisation)
7 Kinetic test-picric acid LKB 8600
Merckotest ref. 3384
(without
deproteinisation)
8 Alkaline picrate Autochemist
(Jaffe)
well as in vivo to link plasma concentrations of ascorbic
acid to quantitative data of interferences in the analytical
method. This aim overlaps with the field of "drug intep
actions" and is regarded as part of clinical pharmacology.
Restricting our attention to the basic program, we have
been able to reduce errors and misleading conclusions to
a minimum by exclusion of interlaboratory, interdis-
ciplinary, economic and political-specific and unspecific
interests and influences.
The coupling of a method to one instrument by a
manufacturer may force the responsible clinical chemist
to use methods with a higher risk of drug interference:
in such a case, method, kit or machine should be
changed. Considering the consumption of ascorbic acid
as vitamin tablets, juices, vegetables and fruits (including
canned food with ascorbic acid as preservative), especially
when there is a risk of infection the clinical chemist and
Objectives Methods
Aspartate amihO-
transferase
UV-test, kinetic, opt. 25°C1)
UV-test, kinetic, non opt. 37°C1)
UV-test, end point1)
Colorimetrictest1)
Phosphatase, alkaline Kinetic-test, p--nitropheny 1 phosphate l)2)
Kinetic-test, phenyl disodium
phosphate2)
Kinetic^test, 4^ammoantipyrin-disodium-
hydrogencarbonat2)
Bilirubin
Calcium
Cholesterol, total
Creatinine
Glucose
Sulfanilic acidrcaifein1)
Dichloraniline-nitrite'1)
o-CresplphthaJeiri-complexp n
Thymolphthalein-complexo n
Flamephotometry
Calcein-titration
Acetic anhydride-acetic acid
Huang, Liebermann·Burchard, Watson
Esterase/oxidase-catalase
Esterase-hydrpgen peroxidase
(Alkaline picrate (Jaffe) without
deproteinisation or with dialysis)
Hexokinase/glucose-6-phosphate
dehydrogenase
Glucose dehydrogenase
Phosphate, inorganic Molybdate-hydroquinone-ascorbate
Molybdate^-methylaminophenplsulfate
Mplybdate-vanadate
Protein, total Biuret-reaction
Urea Diacetyl-monoxime methods
Ur ease-Serf A e/of
UreaseTglutaniate dehydrpgenase .
Urease-nitroprusside-phenol
Uric acid Uricase, Kageyämä's reaction
() = Interference at higher concentrations of ascorbic acid.
A) No clear conclusion by reason of non systematic variations.
2) No clear conclusion by reason of technical problems.
Tab. 4. Analytical methods regarded as being less recommendable.
Objective Method
Glucose
Uric acid
Creatinine
Glucose oxidase methods with indicator
reaction
Neocuprpin methods
All phosphotungstic methods
Uricase methods with copper reduction
Uricase-hydrazone methods
Picrate methods without deprpteini-
sation preceded by dialysis
(Picric acid, kinetic tests, depending on
different type of. reagents or kits)
() = Interference at higher concentrations of ascorbic acid.
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1.2
1.0
0.8
ι ι
0.71 1.42 2.84 5J58 11.36
Ascorbic Qcidlmmol/l]
Fig. 4. Interference by ascorbic acid in phosphate tests.
2, 3, 5, 6 Molybdic acid- SMA 12/60
s tan no u s chloride-
hydrazine
1 Molybdate-p-methyl- Eppendorf
aminophenol Sulfate, 1101
Merckotest ref. 3331
7 Molybdate-vanadate, LKB 7400
Boehringer ref. 15920
8 Molybdate4iydro- Autochemist
quinone
physician may indeed expect ascorbic acid interference
in some of his analyses. Part of the aim of this European-
Communities-Study was to assist his decision in using
more reliable methods.
The study will be concluded by pilot investigations on
the influence of ascorbic acid on the qualitative and
semiquantitative determination of urinary glucose, by
glucose oxidase-paper strip combinations.
This study has been partially supported by the European
Communities.
Dr. K. L. Lauert
Commission des Communautes Eiiropeennes
Bureau Communautaire de Reference
Rue de la Loi 200
Joyeuse Entree 4-21
B-1040 Bruxelles
Prof. G. Siest
Laboratoire de Biochemie - Faculte des Sciences
Pharmaceutiques et Biologiques
7, rue Albert Lebrun
B.P. 3102
F-54013Nancy cedex
Dr. Walter Appel (for the authors)
Priv. Doz., Dipl. Chem.
Zentrallaboratorium der St.-Vincentius-Krankcnh user
D-7500 Karlsruhe
Annexe
General protocol of analytical interference by ascorbic
acid
6 specimens were analysed in duplicate on each of three days.
Materials provided
- Ascorbic acid
— Bottles lyophilised serum (to make 10 ml after reconstitution)
Procedure
1. Prepare a 11.36 mmol/1 (2 g/1) ascorbic acid solution in
redistilled water
2. Preparation of overloaded serum
a) Using this solution daily reconstitute two bottles of lyo-
philised serum (using 10 ml)
b) Mix the contents of the two bottles
3. Preparation of control serum
a) Dissolve four bottles of lyophilised serum daily in redistilled
water (using 10 ml)
b) Mix the contents of the four bottles
4. Preparation of specimens for analyses
Prepare the following dilutions:
Specimen
No.
Concentrations of
ascorbic acid obtained
Overloaded Control
serum serum
mmol/1 g/1
1
2
3
4
5
6
0
0.14
0.43
0.71
1.42
2.84
0
0.025
0.075
0.125
0.25
0.5
0 ml
0.1 ml
0.3ml
0.5ml
1 ml
2 ml
8 ml
7.9ml
7.7ml
7.5ml
7 ml
6 ml
N.B.: Prepare all serum and the ascorbic acid solution fresh daily
5. Assesment of interferences
On each of the above dilutions perform the analyses, in
duplicate and in order of increasing concentrations
6. Results
a) Specify the methods and instruments used
b) Indicate the analytic variation coefficient of your technique
in the zone of values we are concerned with.
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